The role of antiplatelet therapy in the management of ischemic stroke: implementation of guidelines in current practice.
OBJECTIVE
To review and discuss evidence-based guideline recommendations for the use of antiplatelet agents for secondary prevention in patients with ischemic stroke or TIA.


METHODS
A literature search was conducted on PubMed through August 2007 using combinations of the following search terms: aspirin, clopidogrel, dipyridamole plus aspirin, transient ischemic attack, secondary prevention, stroke and guidelines.


RESULTS
Modification of risk factors such as hypertension, diabetes, hypercholesterolemia, cigarette smoking and obesity are fundamental to stroke management. Antiplatelet therapy is highly effective in reducing the risk of recurrent vascular events and is recommended over oral anticoagulants for non-cardioembolic stroke. Evidence from head-to-head comparative clinical trials versus aspirin monotherapy has shown that clopidogrel and the combination of aspirin plus dipyridamole are safe and effective therapeutic options.


CONCLUSIONS
Despite the availability of evidence-based guidelines, recommended interventions are largely underutilized. Quality improvement initiatives such as the ASA's Get with the Guidelines--Stroke and the UCLA stroke PROTECT Program have demonstrated effectiveness in increasing adherence to recommended therapies and thereby improving patient outcomes.
Biller
José
J
Department of Neurology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, USA. jbiller@lumc.edu
D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine / Q000706:statistics & numerical data; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic / Q000592:standards*; D012308:Risk Management / Q000379:methods; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors